Jan 12, 2026 08:00AM
Dec 19, 2025 08:00AM
Dec 19, 2025 08:00AM
Nov 6, 2025 04:00PM
Oct 27, 2025 08:00AM
Oct 13, 2025 06:42AM
Jun 2, 2025 07:30AM IN8bio, Inc (INAB) Presents Positive Phase 1 Data of INB-200
Jun 2, 2025 07:30AM
Mar 13, 2025 04:05PM
Feb 14, 2025 09:00AM
Feb 14, 2025 09:00AM
Nov 12, 2024 04:26PM
Sep 4, 2024 04:02PM
Sep 4, 2024 04:01PM IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
Aug 12, 2024 08:06AM
Aug 12, 2024 08:05AM
Jun 13, 2024 04:01PM
Jun 13, 2024 04:01PM
Apr 30, 2024 06:05AM
Nov 10, 2023 07:00AM
Oct 12, 2023 08:00AM IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of IN
Sep 19, 2023 08:03AM
Aug 10, 2023 04:15PM
May 12, 2023 08:00AM
Apr 25, 2023 08:02AM
Apr 25, 2023 08:00AM
Mar 30, 2023 04:15PM
Jan 5, 2023 07:03AM IN8bio, Inc (INAB) Provides INB-200 Clinical Update, Outlines 2023 Pipeline Goals
Jan 5, 2023 07:00AM
Dec 8, 2022 07:07AM
Dec 8, 2022 07:00AM
Nov 10, 2022 07:30AM
Aug 12, 2022 04:17PM
Aug 12, 2022 04:15PM
Jul 12, 2022 08:00AM IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
Apr 13, 2022 08:30AM
Mar 28, 2022 08:04AM
Mar 28, 2022 08:00AM
Jan 6, 2022 07:00AM
Jan 6, 2022 07:00AM
Dec 16, 2021 07:04AM
Dec 16, 2021 07:00AM IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Nov 16, 2021 07:02AM
Nov 16, 2021 07:00AM
Oct 27, 2021 07:04AM
Oct 27, 2021 07:00AM
Sep 10, 2021 04:15PM
Aug 11, 2021 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All